Adaptive Biotechnologies and Collaborators to Highlight New clonoSEQ and immunoSEQ Data at ASCO 2019
clonoSEQ is also the first clinical diagnostic assay powered by immunosequencing to receive FDA clearance.
Adaptive Biotechnologies and its collaborators will present data from
more than 15 studies for clonoSEQ® and immunoSEQ®
at the American Society of Clinical Oncology (ASCO) Annual Meeting in
Chicago, May 31 – June 4.
“At Adaptive, we are decoding the adaptive immune system to help
diagnose and treat disease. With our FDA-cleared NGS MRD Assay,
clonoSEQ, we are enabling physicians in clinical practice to monitor and
track a patient’s minimal residual disease (MRD) status to predict
outcomes and guide treatment decisions. Additionally, our immunoSEQ
research tool is helping to validate response to immunotherapies and
assess toxicity,” said Chad Robins, CEO and co-founder of Adaptive
Biotechnologies. “We remain committed to expanding the clinical
applications of our immune medicine platform to reach greater numbers of
patients.”
clonoSEQ at ASCO
New clonoSEQ data will continue to demonstrate the impact of our Assay
on assessing and monitoring MRD from a patient’s bone marrow sample for
approved indications, such as multiple myeloma, as well as other blood
cancers uses, such as Chronic Lymphocytic Leukemia (CLL) and Diffuse
Large B-cell Lymphoma (DLBCL). Additionally, we will see increased use
of clonoSEQ in studies to help assess treatment response for novel
therapies like CARTs and anti-CD38. These new data support the need for
a standardized, sensitive, reliable MRD test in multiple disease
settings, across numerous therapies, as well as the importance of MRD
monitoring in a real-world clinical setting.
clonoSEQ presentations of interest include:
| Abstract | Title | Date, location, Time | ||
|
Oral Presentation |
Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results |
Sunday, June 2, 10:45 a.m. CT, Location: E451 | ||
|
Oral Presentation |
A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) |
Sunday, June 2 at 10:57 a.m. CT, Location: E451 | ||
|
Poster Presentation
Poster 306 |
Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis |
Monday, June 3, 8:00 – 11:00 a.m., CT Location: Hall A | ||
|
Poster Presentation
Poster 352 |
Minimal residual disease (MRD) clinical monitoring and depth of response in multiple myeloma |
Monday, June 3, 8:00 – 11:00 a.m. CT, Location: Hall A | ||
|
Oral Presentation |
TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) |
Tuesday, June 4 at 9:57 a.m. CT, Location: E451 | ||
|
Oral Presentation |
Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD–) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities |
Tuesday, June 4, 10:09 a.m. CT, Location: E451 |
immunoSEQ at ASCO
immunoSEQ is being used in the research setting to predict response to
immunotherapies and to monitor toxicity in solid tumors including
pancreatic cancer. Data for immunoSEQ will demonstrate how the product
is being used in large-scale clinical trials. Specifically, data will
highlight how immunoSEQ can help to identify predictive biomarkers, as
well as assess longitudinally patient response to therapies, including
checkpoint inhibitors, Fc enhanced monoclonal antibodies, and cancer
vaccines.
immunoSEQ presentations of interest include:
| Abstract | Title | Date, location, Time | ||
|
Poster 367 |
Clonal expansion of tumor infiltrating leukocytes (tils) in the peripheral blood of metastatic melanoma patients is significantly associated with response to CTLA4 blockade-based immunotherapy |
Saturday, June 1, 8:00 – 11:00 a.m. CT, Location: Hall A | ||
|
Poster 111 |
High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc-enhanced anti-HER2 monoclonal antibody (mAb) |
Sunday, June 2, 8:00-11:00 a.m. CT, Location: Hall A |
About the clonoSEQ Assay
The clonoSEQ Assay is the first and only FDA-cleared in vitro
diagnostic assay for the detection and monitoring of minimal residual
disease (MRD) in patients with multiple myeloma (MM) and B-cell acute
lymphoblastic leukemia (ALL) using DNA from bone marrow samples.
clonoSEQ is also the first clinical diagnostic assay powered by
immunosequencing to receive FDA clearance. It leverages Adaptive’s
proprietary immunosequencing platform to identify and quantify specific
DNA sequences found in malignant cells, allowing clinicians to assess
and monitor MRD during and after treatment. The assay provides
standardized, accurate and sensitive measurement of MRD that allows
physicians to predict patient outcomes, assess response to therapy over
time, monitor patients during remission and detect potential relapse.
Clinical practice guidelines in hematological malignancies recognize
that MRD status is a reliable indicator of clinical outcomes and
response to therapy, and clinical outcomes are strongly associated with
MRD levels measured by the clonoSEQ Assay in patients diagnosed with ALL
and MM. clonoSEQ testing is covered by Medicare in alignment with the
FDA label.
clonoSEQ is a single-site assay performed at Adaptive Biotechnologies.
It is also available as a CLIA-regulated laboratory developed test (LDT)
service for use in other lymphoid cancers. For important information
about the FDA-cleared uses of clonoSEQ, including the full intended use,
limitations, and detailed performance characteristics, please visit www.clonoSEQ.com/technical-summary.
About immunoSEQ Assay
Adaptive’s immunoSEQ Assay helps researchers make discoveries in areas
such as oncology, autoimmune disorders, infectious diseases and basic
immunology. The immunoSEQ Assay can identify millions of T- and B-cell
receptors from a single sample in exquisite detail. Offered as a Service
or Kit, the immunoSEQ Assay is used to ask and answer translational
research questions and discover new prognostic and diagnostic signals in
clinical trials. The immunoSEQ Assay provides quantitative, reproducible
sequencing results along with access to powerful, easy-to-use analysis
tools. The immunoSEQ Assay is for research use only and is not for use
in diagnostic procedures.
About Adaptive Biotechnologies
Adaptive Biotechnologies is a pioneer and leader in immune-driven
medicine that aims to improve people’s lives by learning from the wisdom
of their adaptive immune systems. Adaptive’s proprietary immune medicine
platform reveals and translates insights from our adaptive immune
systems with unprecedented scale and precision. Working with drug
developers, clinicians and academic researchers, we are applying these
insights to develop products that will transform the way diseases such
as cancer, autoimmune conditions, and infectious diseases are diagnosed
and treated. For more information, please visit adaptivebiotech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005844/en/